Antimalarial drugs & diagnostic testing in the era of subsidies: multi-country findings - Presentation
Presented in Basel in October 2012 at the 'Challenges in malaria research' meeting, hosted by BioMed Central in conjunction with its journals Malaria Journal and Parasites & Vectors.
Press Release - MIM 2013 - First-ever drug compound developed on African soil, an antimalarial, to move to human trials - Durban, South Africa | 8 October 2013
This press release was shared by the Roll Back Malaria Malaria Advocacy Working Group during the 6th MIM Pan-African Malaria Conference. Among others, it features Myanmar's efforts to increase the availability of ACT, measured by national surveys based on the ACTwatch model.
O’Connell et al., Malaria Journal 2013, 12:52 http://www.malariajournal.com/content/12/1/52
Presented at the 6th MIM Pan-African Malaria Conference, 2013 (MIM 2013) in Durban in October 2013.
The table outlines all oral artemisinin monotherapy (oAMT) products found during 2013 ACTwatch surveys. Photos are included where available. Among 6 countries surveyed in 2013, oral AMT was found to be available in the DRC, Cambodia, Myanmar, and Nigeria. No oral AMT was found in Madagascar or Uganda.
This report highlights key trends and most recent findings regarding antimalarial markets across 8 of the ACTwatch sub-Saharan African countries.